Lundbeck executive remains confident about Alzheimer's drug after new analysis

Even though Rexulti did not deliver quick results in phase III against Alzheimer's disease, Lundbeck's Head of R&D Johan Luthman still sees plenty of potential in the trial which is now set to be concluded in the new year.
Lundbeck EVP and Head of R&D Johan Luthman | Photo: PR / Lundbeck
Lundbeck EVP and Head of R&D Johan Luthman | Photo: PR / Lundbeck
BY ELIZABETH MØNSTED JOHANSEN & ULRICH QUISTGAARD, TRANSLATED BY NIELSINE NIELSEN

Danish pharmaceutical company Lundbeck had hoped for quick, efficient results in the third clinical trial with Rexulti as a treatment for agitation in Alzheimer's patients, but this hope was soon extinguished.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading